Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 6/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.32 |
| ▸ | BRAF | P15056 | 11/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10267990 | 0.77 | PDE3B (0.40) | PDE3BPDE3ARAF1CRBNBRAF | |
| SCHEMBL797188 | 0.75 | HTR2A (0.38) | PDE3BPDE3ARAF1BRAFCYP19A1 | |
| SCHEMBL22940330 | 0.74 | CRBN (0.36) | PDE3BPDE3ARAF1CRBNBRAF | |
| SCHEMBL30116209 | 0.74 | RAF1 (0.38) | PDE3BPDE3ARAF1CRBNBRAF | |
| SCHEMBL346352 | 0.74 | SRD5A1 (0.44) | RAF1CRBNBRAFEGFR | |
| SCHEMBL3009275 | 0.74 | DAO (0.37) | PDE3BPDE3ARAF1CRBNBRAF | |
| SCHEMBL10298268 | 0.74 | RAF1 (0.38) | PDE3BPDE3ARAF1CRBNBRAF | |
| SCHEMBL10199838 | 0.73 | HTR2A (0.37) | PDE3BPDE3ARAF1CRBNBRAF | |
| SCHEMBL782837 | 0.73 | PDE3B (0.38) | PDE3BPDE3ARAF1CRBNBRAF | |
| SCHEMBL20597761 | 0.73 | RAF1 (0.43) | RAF1BRAFCYP19A1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | PDE3B 953/4885PDE3A 1364/4885RAF1 219/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | PDE3B 1572/4885PDE3A 2568/4885RAF1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.